AzTrials
AzTrials

Cognitive Impairment Associated With SchizophreniaPhase 2TALLYNCT03745820

A Study to Evaluate the Safety and Efficacy of BIIB104 in Participants With Cognitive Impairment Associated With Schizophrenia (CIAS)

A Phase 2 study testing BIIB104 in people with Cognitive Impairment Associated With Schizophrenia, run by Biogen at 60 sites in 5 countries.

Completed

Finished. The study has ended and is not enrolling. Results may be posted on the official record.

Official record
Search all trials

Trial summary

The primary objective of the study is to evaluate the efficacy of BIIB104 in participants with CIAS, using the Working Memory Domain of the MATRICS Consensus Cognitive Battery (MCCB). Read more about this study

Who is it for?
Ages 18 to 55 years
What is being tested?
BIIB104
Type of treatment
Pill or oral medicine
Could I receive a placebo?
Yes, some participants may receive a placebo
How many people
195 participants
Where
60 sitesin 5 countries
Study dates
15 Nov 2018to 7 Apr 2022
Phase
Phase 2
Are there results?
Yes, posted in the registrySummary in the doctors' view

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 to 55 years
  • All sexes
  • No healthy volunteers
  • Adult

Who may be able to join

  • Otherwise healthy participant with a Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-5), diagnosis of schizophrenia of at least 2 years' duration as confirmed by the mini-international neuropsychiatric interview (MINI) 7.0.2 for Psychotic Disorders.
  • Evidence of stable schizophrenia symptomatology ≥12 weeks (e.g., no hospitalizations for schizophrenia, no increase in level of psychiatric care due to worsening of schizophrenia symptoms).
  • Participants must be in ongoing maintenance atypical antipsychotic therapy (except clozapine), on a stable treatment regimen for ≥8 weeks prior to Baseline/Day 1, including concomitant psychotropic medication. Doses of background atypical antipsychotics should be within the recommended dose range listed in the approved product labeling of the country where the study is being conducted.
  • SCI-PANSS: No more than moderate-severe rating (score ≤5) on delusions, hallucinatory behavior, grandiosity, suspiciousness / persecution, and hostility (i.e. PANSS, positive symptom items P1, P3, P5, P6, P7); or unusual thought content (G9); and no more than a moderate rating (score ≤4) on conceptual disorganization (P2).

Who cannot join

  • Participation in a trial using any component or version of the MATRICS Consensus Cognitive Battery (MCCB) or the University of California, San Diego (UCSD) Performance-Based Skills Assessment test within the previous 6 months.
  • Participation in cognitive remediation therapy within 6 months prior to randomization.
  • Screening MCCB Working Memory Domain T-score ≥60.
  • Current DSM-5 diagnosis of schizoaffective disorder on the MINI 7.0.2 for Psychotic Disorders.
  • Current DSM-5 diagnosis of major depressive episode, manic and hypomanic episode, panic disorder, agoraphobia, social anxiety disorder, obsessive-compulsive disorder, posttraumatic stress disorder, and/or generalized anxiety disorder on the MINI 7.0.2 for Psychotic Disorders.
  • Lifetime DSM-5 diagnosis of antisocial personality disorder, anorexia nervosa, bulimia nervosa, and/or binge-eating disorder on the MINI 7.0.2 for Psychotic Disorders.
Show all 9Show fewer
  • Meets the DSM-5 diagnosis of moderate or severe substance use disorder (excluding nicotine dependence) within 12 months of screening on the MINI 7.0.2 for Psychotic Disorders interview.
  • DSM-5 diagnosis of Intellectual Disability (intellectual developmental disorder).
  • NOTE: Other protocol defined Inclusion/Exclusion criteria may apply.

Trial locations and contacts

60 sites in 5 countries.

60 sites in 5 countries

United States37 sites
  • Atlanta Center for Medical Research

    Atlanta, Georgia, 30331

  • Augusta University

    Augusta, Georgia, 30912

  • Pillar Clinical Research, LLC

    Bentonville, Arkansas, 72712

  • Hassman Research Institute

    Berlin, New Jersey, 08009

  • UB Department Psychiatry

    Buffalo, New York, 104051

  • Neurobehavioral Research, Inc.

    Cedarhurst, New York, 11516

  • Research Site

    Chicago, Illinois, 60611

  • The Ohio State University Department of Psychiatry

    Columbus, Ohio, 43210

  • ProScience Research Group

    Culver City, California, 90230

  • Research Site

    Decatur, Georgia, 30030

  • Research Site

    Flowood, Mississippi, 39232

  • Research Site

    Gaithersburg, Maryland, 20877

  • Collaborative Neuroscience Network, LLC

    Garden Grove, California, 92845

  • Cherry Health

    Grand Rapids, Michigan, 49503

  • Alexian Brothers Hospital Network

    Hoffman Estates, Illinois, 60169

  • Research Site

    Kirkland, Washington, 98033

  • Research Site

    Lauderhill, Florida, 33319

  • Synergy San Diego

    Lemon Grove, California, 91945

  • Research Site

    Long Beach, California, 90807

  • Premier Clinical Research Institute, Inc.

    Miami, Florida, 33122

  • Catalina Research Institute, LLC

    Montclair, California, 91763

  • Yale University, Department of Psychiatry

    New Haven, Connecticut, 06519

  • Research Site

    North Canton, Ohio, 44720

  • Excell Research

    Oceanside, California, 92056

  • Research Site

    Pico Rivera, California, 90660

  • Research Site

    Richardson, Texas, 75080

  • Finger Lakes Clinical Research

    Rochester, New York, 14618

  • The University of Texas Health Science Center at San Antonio

    San Antonio, Texas, 78207

  • CNRI - San Diego, LLC

    San Diego, California, 92102

  • Artemis Institute for Clinical Research

    San Diego, California, 92103

  • Research Site

    San Diego, California, 92123

  • Research Site

    San Rafael, California, 94901

  • Southern Illinois University, School of Medicine

    Springfield, Illinois, 62702

  • Research Site

    St Louis, Missouri, 63128

  • St. Louis Clinical Trials, LC

    St Louis, Missouri, 63141

  • Stedman Clinical Trials

    Tampa, Florida, 33613

  • Research Site

    Torrance, California, 90502

Other trials in United States

Japan9 sites
  • Research Site

    Anan-shi

  • Research Site

    Ichikawa-shi

  • Research Site

    Kashihara-shi

  • Research Site

    Kawasaki-shi

  • Research Site

    Kita-gun

  • Research Site

    Kodaira-shi

  • Research Site

    Kumagaya-shi

  • Research Site

    Takasaki-shi

  • Research Site

    Yokosuka-shi

Other trials in Japan

Spain7 sites
  • Hospital Clinic de Barcelona

    Barcelona, 08036

  • Hospital Universitario 12 de Octubre

    Madrid, 28040

  • Research Site

    Majadahonda, Madrid, 28222

  • Research Site

    Oviedo, Principality of Asturias, 33011

  • Unidad Neurociencias CS San Juan

    Salamanca, 37005

  • Hospital Universitario Marques Valdecilla

    Santander, Cantabria, 39008

  • Research Site

    Seville, 41013

Other trials in Spain

Germany4 sites
  • Zentrum für klinische Forschung Dr. med. I. Schöll

    Bad Homburg, Hesse, 61348

  • Clinic for Psychiatrie

    Frankfurt am Main, Hesse, 60528

  • Dpt of Psychiatry and Psychotherapy, University of Leipzig

    Leipzig, Saxony, 04103

  • Universitätsmedizin Göttingen, Klinik für Psychiatrie und Psychotherapie

    Westerstede, Lower Saxony, 26655

Other trials in Germany

United Kingdom3 sites
  • Research Site

    London, SE5 8AZ

  • Abraham Cowley Unit

    Lyne, Surrey, KT16 0AE

  • Oxford Health NHS Foundation Trust

    Oxford, Oxfordshire, OX3 7JX

Other trials in United Kingdom

About this study

Official title: A Phase 2, Randomized, Double-Blind, Multiple-Dose, Placebo-Controlled Study to Evaluate the Safety and Efficacy of BIIB104 in Subjects With Cognitive Impairment Associated With Schizophrenia (CIAS)

The primary objective of the study is to evaluate the efficacy of BIIB104 in participants with CIAS, using the Working Memory Domain of the MATRICS Consensus Cognitive Battery (MCCB).

The secondary objectives of this study are to evaluate the safety and tolerability of BIIB104 in participants with CIAS, and to evaluate the efficacy of BIIB104 in participants with CIAS on measures of cognition, functioning, and psychiatric symptomology.

Being tested
BIIB104, Placebo

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • BIIB104Drug

    Also called PF-04958242

    Administered as specified in the treatment arm

  • PlaceboOther

    Administered as specified in the treatment arm

Study groups in NCT03745820
Study groupRoleWhat they receive
BIIB104 0.5 mgExperimentalParticipants will receive 0.5 mg of BIIB104 twice a day, orally, for 12 weeks.
Receives: Drug: BIIB104
BIIB104 0.15 mgExperimentalParticipants will receive 0.15 mg of BIIB104 twice a day, orally, for 12 weeks.
Receives: Drug: BIIB104
Matching PlaceboPlacebo comparatorParticipants will receive matching placebo twice a day, orally, for 12 weeks.
Receives: Other: Placebo

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Change From Baseline in Change From Baseline in Measurement and Treatment Research to Improve Cognition in Schizophrenia (MATRICS) Consensus Cognitive Battery (MCCB) Working Memory Domain Score at Week 12

    The MCCB is a cognitive battery that assesses 7 domains recommended by the MATRICS initiative (i.e., Working Memory, Verbal Learning, Speed of Processing, Attention/Vigilance, Visual Learning, Social Cognition, and Reasoning and Problem Solving). MCCB was administered via laptop computer and paper-and-pencil assessments. T-scores for the individual tests were calculated according to the developer's recommended scoring algorithms. MCCB composite T scores are between 40 and 60 (normal range). Higher scores indicate better cognitive functioning. The working memory domain score of the MCCB is reported in this outcome measure.

    Measured: Baseline and Week 12

Secondary outcomes (10)
  1. Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs)

    An AE is any untoward medical occurrence in a participant or clinical investigation participant administered a pharmaceutical product and that does not necessarily have a causal relationship with this treatment. An SAE is any untoward medical occurrence that at any dose results in death, places the participant at immediate risk of death, requires inpatient hospitalization or prolongation of existing hospitalization, results in persistent or significant disability/incapacity, results in a congenital anomaly/birth defect, or is a medically important event.

    Measured: From first dose of study drug through end of the study (up to Week 14)

  2. Mean Total Score Assessed by Scale for the Assessment and Rating of Ataxia (SARA)

    The SARA is a clinical scale that is based on a semiquantitative assessment of cerebellar ataxia on an impairment level and complements the brief neurological examination. The SARA scale is an eight-item clinical rating scale (gait, stance, sitting, speech, finger-chase test, nose-finger test, fast alternating movements, and heel-shin test) with a total score range of 0-40, where 0 is the best neurological status and 40 is the worst neurological status.

    Measured: Baseline, Weeks 2, 6, 12 and safety follow-up (Week 14)

  3. Number of Participants With at Least One Event of Suicidal Ideation and/or Suicidal Behavior as Assessed by Columbia-Suicide Severity Rating Scale (C-SSRS) Score

    The C-SSRS is an interview-based rating scale to systematically assess suicidal ideation and suicidal behavior. Suicidal ideation is classified on a 5-item scale: 1 (wish to be dead), 2 (nonspecific active suicidal thoughts), 3 (active suicidal ideation with any methods [not plan] without intent to act), 4 (active suicidal ideation with some intent to act, without specific plan), and 5 (active suicidal ideation with specific plan and intent). Suicidal behavior is classified on a 6-item scale: 1 (actual attempt), 2 (interrupted attempt), 3 (aborted attempt), 4 (preparatory acts or behavior), 5 (suicidal behavior), and 6 (suicide). The data analyzed signifies the participants with at least one event of suicidal ideation and/or suicidal behavior.

    Measured: Up to Week 14

  4. Change From Baseline in University of California, San Diego Performance Based Skills Assessment-Brief International Version (UPSA-Bi) Assessment at Week 12

    The UPSA-Bi, international version, an abbreviated version of the UPSA-Validation of Intermediate Measures, is a measure of functional capacity and assesses skills used in community tasks. This assessment measures 2 general skills that were previously identified as essential to functioning in the community: financial skills and communication skills. The UPSA-Bi assessment is scored from 0-100, higher scores indicating higher functional status.

    Measured: Baseline and Week 12

  5. Change From Baseline in Schizophrenia Cognition Rating Scale (SCoRS) Assessment Score at Week 12

    The SCoRS is an interview-based assessment of cognition that involves interviews with participants and informants. The SCoRS includes 20 items designed to specifically assess aspects of cognitive functioning found in each of the seven MCCB cognitive domains including the following: Memory: 4 items; Learning: 2 items; Attention: 3 items; Working memory: 2 items; Problem solving: 3 items; Processing/motor speed: 2 items; Social cognition: 3 items; Language: 1 item. Total score range is 20-80, lower scores indicating higher functional status. The data reported in this outcome measure are for global rating score.

    Measured: Baseline and Week 12

  6. Change From Baseline in MCCB Neurocognitive Composite Scores at Week 12

    The MCCB is a cognitive battery that assesses 7 domains recommended by the MATRICS initiative (i.e., Working Memory, Verbal Learning, Speed of Processing, Attention/Vigilance, Visual Learning, Social Cognition, and Reasoning and Problem Solving). MCCB was administered via laptop computer and paper-and-pencil assessments. T-scores for the individual tests were calculated according to the developer's recommended scoring algorithms. MCCB composite T scores are between 40 and 60 (normal range). Higher scores indicate better cognitive functioning. The MCCB composite score contains all of the tests and domains of the MCCB.

    Measured: Baseline and Week 12

  7. Change From Baseline in MCCB Individual Domain Scores (Excluding Working Memory Domain) at Week 12

    The MCCB is a cognitive battery that assesses 7 domains recommended by the MATRICS initiative (i.e., working memory, verbal learning, speed of processing, attention/vigilance, visual learning, social cognition, and reasoning and problem solving). MCCB was administered via laptop computer and paper-and-pencil assessments. T-scores for the individual tests were calculated according to the developer's recommended scoring algorithms. MCCB composite T scores are between 40 and 60 (normal range). Higher scores indicate better cognitive functioning. All the domain scores of the MCCB are reported in this outcome measure with the exception of working memory domain.

    Measured: Baseline and Week 12

  8. Change From Baseline in Positive and Negative Syndrome Scale (PANSS) Total Score, Positive Subscale, and Negative Subscale Scores at Week 12

    The PANSS includes 3 subscales and 30 items: 7 items that make up the Positive subscale (e.g., delusions, conceptual disorganization, hallucinatory behaviour); 7 items that make up the Negative subscale (e.g., blunted affect, emotional withdrawal, poor rapport, passive/apathetic social withdrawal); and 16 items that make up the General Psychopathology subscale (e.g., somatic concern, anxiety, guilt feelings, mannerisms and posturing, motor retardation, uncooperativeness, disorientation, poor impulse control, preoccupation). Each item on the positive, negative and general psychopathology subscale is rated from 1 (absent) to 7 (extreme). The score range is 7-49 for positive and negative subscales, score range is 16-112 for the general psychopathology subscale. Total PANSS score (positive+ negative + general psychopathology subscale scores) range from 30 to 210. Higher scores represent more severity in symptoms.

    Measured: Baseline and Week 12

  9. Change From Baseline in Clinical Global Impression-Severity (CGI-S) Scores at Week 12

    The CGI-S consists of a single 7-point rating score of illness severity. The following question: "Considering your total clinical experience with this particular population, how mentally ill is your participant at this time?" is rated with a score from 1 to 7- 1: Normal, not ill at all; 2: Borderline mentally ill; 3: Mildly ill; 4: Moderately ill; 5: Markedly ill; 6: Severely ill; or 7: Among the most severely ill participants. Lower scores indicate less severity of illness.

    Measured: Baseline and Week 12

  10. Number of Participants With Response on Clinical Global Impression-Improvement (CGI-I) Scale at Week 12

    The CGI-I consists of a single 7-point rating score total improvement, regardless of whether or not the change is due entirely to drug treatment. The following question: "Compared to your participant's condition at the beginning of treatment, how much has your participant changed?" is rated with a score from 1 to 7- 1: Very much improved; 2: Much improved; 3: Minimally improved; 4: No change; 5: Minimally worse; 6: Much worse; or 7: Very much worse. Lower scores indicate greater improvement.

    Measured: Week 12

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted19 Nov 2018
  2. Study start15 Nov 2018
  3. Primary completion23 Mar 2022
  4. Study completion7 Apr 2022

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomised
Intervention model
Parallel groups
Masking
Quadruple blind
Who is masked
Participant, Care provider, Investigator, Outcomes assessor
Enrolment
195 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT03745820
Sponsor's protocol ID
263CS201
Other IDs
2018-003825-27, 2018
Acronym
TALLY
Status last verified
Mar 2023
First submitted
15 Nov 2018
Last updated
18 Apr 2023
Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No

Questions about this trial

What is this clinical trial studying?

A Phase 2 study testing BIIB104 in people with Cognitive Impairment Associated With Schizophrenia, run by Biogen at 60 sites in 5 countries.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 4 inclusion and 9 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: finished, as of the sponsor's last update on 18 Apr 2023. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 60 sites in United States, Japan, Spain, Germany, United Kingdom. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. Some participants in this study may receive a placebo. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

What does this phase mean?

Phase 2 studies give the treatment to a larger group to see whether it has the intended effect and to keep checking safety.

Not every study follows the same path, and some studies (observational studies, device studies) have no phase.

Are results available for this study?

Yes. Results are posted in the registry (first posted 18 Apr 2023). A summary is in the For doctors view, and the full results are on ClinicalTrials.gov.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Change From Baseline in Change From Baseline in Measurement and Treatment Research to Improve Cognition in Schizophrenia (MATRICS) Consensus Cognitive Battery (MCCB) Working Memory Domain Score at Week 12 (time frame: Baseline and Week 12). It is what the study was designed to measure, not a finding.

Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 18 Apr 2023.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in